1 / 24

Pixium Vision at a glance

Pixium Vision at a glance. Founded in December 2011 by Bernard Gilly , Jose Sahel ( IdV ), Ryad Benosman (UPMC ), Philippe Bergonzo (CEA), Serge Picaud ( IdV ), Christoph Posch (AIT) and Lionel Rousseau (ESIEE)

biana
Download Presentation

Pixium Vision at a glance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pixium Vision at a glance • Founded in December 2011 by Bernard Gilly, Jose Sahel (IdV), Ryad Benosman (UPMC), Philippe Bergonzo(CEA), Serge Picaud(IdV), Christoph Posch (AIT) and Lionel Rousseau (ESIEE) • Development and commercialisation of novelgenerationretinalprosthetics) based on combining: • Existingvalidated implant technology, IRIS™ acquiredfrom IMI • Rupture technologyincluding new asynchronoussensor, improved signal processing / stimulationand new 3D electrode-arrays • Based in Paris at the IdV (National EyeHospital, UPMC), International network (ETZH, The Salk Institute, HebrewUniversity, MIT), strong IP and experienced management team

  2. StrongExperienced Leadership Scientific and ClinicalAdvisoryBoard • Jose Sahel (Paris, F) Chairman of the Vision Institute • Mathias Finck (Paris, F) Institut Langevin • E.J. Chichilnisky (San Diego, USA) The Salk Institute • Amir Amedi (Jerusalem, IS) The HebrewUniversity • Tobias Delbruck (Zurich, CH) ETZH • Serge Picaud (Paris, F) Inserm Management team • Bernard Gilly, Executive Chairman (Transgene, Sofinnova, Fovea, Sanofi) • Robert Hill, ChiefOperating Officer (IMI, Medtechindustry) • AurelieGrienenberger, Project Leader (Dyax, Fovea, Sanofi) • Stephan Mattelin, ChiefTechnicalOfficer (Medtronics, AIT) • Ralph Hornig, ChiefMedicalOfficer (IMI)

  3. Why PIXIUM ? Over the past 7 years the Vision Institute teams, withcollaborators (CEA, ESIEE, international) has Accumulated data, knowledge and patents on visualprocessing, electrode design, surfacing, implant design Attractedmathematicalmodelers and world-class experts in bio-inspiredartificial vision Hencetheywillcreate an innovativecompanyaroundnovel implants (design, encoding…) In parallel the clinical team has been involved in the first clinical trials with first generation implants With Second Sight (4 patients, promisingresults) With IMI (1 patient) Hence a strongexpertise in surgicalimplatation and rehabilitation programs In July 2011, Tim Haines (Abingworth, IMI leadinginvestor) and Steffen Suchert (co-founder of IMI) approached JS and BG in order to Relocate IMI to the Vision Institute Foster synergies with the clinical and research teams Restructure the development plan and global strategy Afternumerous exchanges the currentscheme for integration and development has been developped

  4. CompetitiveLandscape

  5. Path to clinic and market 2012 2013 2014 2015 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FIM, 6 patients CE Mark Extension 20 patients Validation IRIS 1 Connexion DVS on Implanted patients CE Mark Preparation connexion DVS In vivo validation Development IRIS 232 DVS, SP FIM Development IRIS 2 3D-diamond-DVS-ATIS In vivo validation

  6. Cost of Blindness • Afterdeath, blindnessis the mostfeareddiseasecomplication • 12M american and 13 M european have irreversiblevisualimpairment • More than 1 M americansage ≥ 40 are legallyblind (≤20/200 acuity) • $ 22,3 b direct costs and $ 16,1 b indirect costsper year (US only)

  7. MarketPotentialAn emergingfieldwithtremendous promises

  8. Restoringfunctionalsight to blind patients • Patients willbe able to recognizefamiliar people • Patients willbe able to recognize the shape of, identify and grasplargerobjects • Patients willbe able to orient themselveseven in an unfamiliarsurroundings • Patients willbe able to live with more autonomy and mobility Before After

  9. The IRIS™ system

  10. Creatingvisual perception

  11. Learning to seeagain

  12. IRIS™ Architecture RI VI PP Retinal Implant (RI) Visual Interface (VI) Pocket Processor (PP)

  13. PIXIUM Improvements on IRIS™ System 3) New visual data acquisition based on “silicon retina” sensor New asynchronous, bio-compatible encoding of visual information and stimulation signals based on mathematical retina models New electrode / implant design and materials (3D interface and diamond) New improved stimulation strategies based on superior knowledge of the biology of the retina and on visual perception 4) 2) 1)

  14. 1) Visual data acquisition: “Silicon Retina” Asynchronous, event-driven acquisition of visual information Bio-compatible spike-based data encoding >120dB dynamic range Sub-millisecond timing precision Biological Model “Silicon Retina” Sensor VLSI Design Electrical Model C Posch, 2012, JINST 7 C01054, doi:10.1088/1748-0221/7/01/C01054

  15. 2) Bio-compatible encoding of stimulation signals based on mathematical retina models

  16. 3) Electrode implant design and materials 120 80 40 0 40 80 120 a) Diamondas a semiconductiveand biocompatible material b) 3D Implant interface diamond polyimide 18 BLO/VSFR1053381, SP37966ID-BD11348 (Djilas et al., 2011)

  17. 4) Improved Stimulation Strategies Modelinglow vision withretinal dystrophies and retinal implants Modelingelectrode stimulations: • Electrode number and density • Gray levels • Electrode configuration • Information coding • Assesslearningstrategies

  18. Proof of Concept: Patient Case Study Implantation surgery on right eye More than 20 stimulation sessions • The patient is able to find and grab a 4-inch ball • Stable stimulation thresholds demonstrate safety of stimulation Implant is well tolerated in the eye 69-year-old blind woman with RP; loss of reading capability 20 years ago

  19. Results from Second Sight® Implant • Implant with60 electrodes • Large variationsbetween patients • Readingletters and short words, orientation • CEE mark: 80 000€

  20. Strong IP accross technologies General stimulation device and concept • Implant coupled with a bi-directional interface to an encoder with learning capabilities • Extra-ocular, epi-retinal implant Electrode / electrode array • A variety of array structures Image processing / encoder / light intensifier • Secured communication, wireless transmission Tack (fixation of implant) • Removable fixation Application-specific integrated circuit (ASIC) chip • Active charge balancing for electrode safety New asynchronous camera sensor DVS-ATIS 3-D electrode arrays (foils) and methodology for doped diamond coating Signal processing and stimulation algorithms

  21. PIXIUM technology roadmap 1st generation • IMI system with DVS camera • Adapted processing 1st generation June 2013 2nd generation • Stimulator ASIC IMI with 232 electrodes • Camera DVS + improved signal processing / stimulation • Wireless communication for forward data path • Foil 232 electrodes (3D and diamond) June 2015 3rd generation(final PIXIUM) • PIXIUM full-custom stimulator ASIC with 600 to 1000 electrodes • DVS and/or new full-custom silicon retina camera • Final processing / stimulation • Final 3D + diamond implant / array December 2018

More Related